Isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases
US12083163B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 9, 2021 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | May 11, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.